EC
ATXS

EntryPoint Capital’s Astria Therapeutics ATXS Stock Holding History

EntryPoint Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,569
Closed -$106K – 660
2025
Q3 		$106K Sell
14,569
-18,806
-56% -$127K 0.04% 617
2025
Q2 		$179K Buy
+33,375
New +$162K 0.09% 508

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EntryPoint Capital's ATXS Position: Q4 2025 in Review

EntryPoint Capital sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 14,569 shares — an estimated $106K sold.

EntryPoint Capital first reported a position in ATXS in Q2 2025 and held it in 2 quarters. The position peaked at $179K in Q2 2025. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • EntryPoint Capital reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EntryPoint Capital sold 14,569 Astria Therapeutics shares in Q4 2025, an estimated $106K.
  • EntryPoint Capital first reported a position in Astria Therapeutics in Q2 2025 and held it in 2 quarters.
  • EntryPoint Capital's Astria Therapeutics position peaked at $179K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.